Lenalidomide and Doxorubicin Hydrochloride Liposome in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

This study has suspended participant recruitment.
(Due to national shortage of Doxil.)
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00903630
First received: May 15, 2009
Last updated: August 22, 2011
Last verified: August 2011

May 15, 2009
August 22, 2011
April 2009
June 2013   (final data collection date for primary outcome measure)
Maximum Tolerated Dose of Lenalidomide [ Time Frame: Beginning from 1st Dose Until Not Tolerated - Phase I ] [ Designated as safety issue: Yes ]
Phase I of study: Lenalidomide at cohort specific assigned dose and schedule (starting at 10 mg by mouth per day on days 1-28) of a 28 day cycle with 40 mg/m^2 of liposomal doxorubicin given intravenously (IV) on day 1 of a 28 day cycle.
Maximum tolerated dose of lenalidomide [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00903630 on ClinicalTrials.gov Archive Site
  • Disease Response At Maximum Tolerated Dose [ Time Frame: 3 and 6 Months ] [ Designated as safety issue: No ]
    Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) criteria defined as one or more lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as > or = 20 mm with conventional techniques (CT, PET/CT, MRI, X-ray) or as > or = 10 mm with spiral CT scan.
  • Time to Disease Progression With Maximum Tolerated Dose [ Time Frame: Beginning from 1st Dose Until Disease Progression ] [ Designated as safety issue: No ]
    RECIST Criteria: Complete Response (CR)- The disappearance of all target lesions. Partial Response (PR)- At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter. Progressive Disease (PD)- At least a 20% increase in the sum of the longest diameters of target lesions or the appearance of one or more new lesion(s). Stable Disease (SD)- Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.
  • Toxicity according to NCI CTCAE v3.0 [ Designated as safety issue: Yes ]
  • Disease response according to RECIST criteria [ Designated as safety issue: No ]
  • Time to progression (duration of response) [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Lenalidomide and Doxorubicin Hydrochloride Liposome in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
WCC #50 - Phase I/II Trial of Lenalidomide in Combination With Liposomal Doxorubicin for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer

RATIONALE: Lenalidomide may stop the growth of cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with doxorubicin hydrochloride liposome may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide when given together with doxorubicin hydrochloride liposome in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

OBJECTIVES:

Phase I - Primary

  • To determine the maximum tolerated dose of lenalidomide when combined with fixed dose pegylated liposomal doxorubicin hydrochloride in women with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Phase II - Define the best overall response induced by lenalidomide in recurrent ovarian cancer patients

Secondary

  • To obtain preliminary information on toxicity, response, and time to progression (duration of response) of these patients.
  • Progression free survival

Phase I OUTLINE: This is a dose-escalation study of lenalidomide. Patients receive oral lenalidomide once daily on days 1-28 and pegylated liposomal doxorubicin hydrochloride intravenously (IV) on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Phase II OUTLINE: The phase II component will include patients with measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) criteria treated at lenalidomide 10 mg days 1-28 days of a 28 day cycle (Maximum Tolerated Dose from phase I) with liposomal doxorubicin 40 mg/m^2 to determine efficacy and safety of the combination therapy. (Effective with April 2010 revision)

After completion of study therapy, patients are followed periodically.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Cavity Cancer
  • Drug: Lenalidomide
    Administered by mouth at the assigned dose; beginning at 10 mg and schedule of each 28 day cycle
    Other Name: Revlimid
  • Drug: pegylated liposomal doxorubicin hydrochloride
    Liposomal doxorubicin at a fixed dose of 40 mg/m^2 intravenously (IV) on day 1 of each 28 day cycle
    Other Name: Caelyx®
Experimental: Lenalidomide with liposomal doxorubicin
Patients treated with a combination of lenalidomide and liposomal doxorubicin fpr recurrent epithelia ovarian, fallopian tube or primary peritoneal cancer.
Interventions:
  • Drug: Lenalidomide
  • Drug: pegylated liposomal doxorubicin hydrochloride
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
51
June 2014
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histological diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer which has recurred or is resistant to prior treatment with at least one platinum based regimen and meeting at least one of the following criteria:

    • Platinum refractory - progression during the first six cycles of first line therapy with a platinum based regimen
    • Platinum resistant - progression within 6 months of completing first line platinum based chemotherapy
    • Platinum sensitive - progression more than 6 months of completing first line platinum based chemotherapy
    • Disease that has progressed while receiving or recurred within 6 months of completing platinum based second-line therapy Patients who have failed a second line therapy more than 6 months after completing treatment or have had more than 2 prior chemotherapy regimens will not be eligible for this study.
  • Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) criteria defined as one or more lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as > or = 20 mm with conventional techniques (CT, PET/CT, MRI, X-ray) or as > or = 10 mm with spiral CT scan.

Patients entering the study during the dose escalation component who do not meet the measurable disease requirement may enter with elevated CA 125 levels only if previously normal or stable CA 125 levels are documented after the completion of the prior chemotherapy regimen.

  • Age > or = 18 years at the time of signing of consent form
  • Gynecologic Oncology Group (GOG) performance status of < or = 2
  • Laboratory test results within these ranges within 14 days prior to study registration:

    • Absolute neutrophil count > or = 1.5 x 10^9/L
    • Platelet count > or = 100 x 10^9/L
    • Serum creatinine < or = 1.5 mg/dL
    • Total bilirubin < 1.2 mg/dL
    • AST (SGOT) and ALT (SGPT) < or = 2 x upper limit of institutional normal (ULN) or < or = 5 x ULN if hepatic metastases are present.
  • The left ventricular ejection fraction must be at or above the lower institutional limits of normal (as assessed by MUGA scan or echocardiogram) obtained within 28 days prior to registration.
  • Peripheral neuropathy ≤ grade 2 (CTCAE v 3.0).
  • Patients who are taking a stable or decreasing dose of concomitant systemic steroids during the study must agree to also take low dose aspirin and/or other platelet-active, anti-thrombotic medication (medication[s] used will be decided by the Investigator) while receiving study drug and for 30 days after study drug is discontinued.
  • All previous cancer therapy, including chemotherapy, hormonal therapy and surgery, must have been discontinued at least 28 days prior to treatment in this study. Use of thalidomide, or structurally related compounds, radiation, or biologic response modifiers must be discontinued at least 2 weeks prior to treatment in this study.
  • Progression free of prior malignancies for > or = 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
  • Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
  • Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin)
  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

    • A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

Exclusion criteria:

  • Histologic diagnosis of borderline or low malignant potential epithelial carcinoma.
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that, in the opinion of the investigator, would prevent the patient from signing the consent form.
  • Prior history of myocardial infarction, congestive heart failure, or arrhythmia requiring medication. History of uncontrolled hypertension. History of systolic or diastolic dysfunction. EKG evidence of ventricular hypertrophy, conduction abnormality, or serious arrhythmia.
  • History of deep vein thromboembolism (DVT) within the previous 6 months, history of thrombocytopenia or bleeding disorders.
  • Pregnant or breast feeding females. Lenalidomide is pregnancy category X.
  • Any condition, including the presence of laboratory abnormalities, which places the patient at unacceptable risk if she were to participate in the study or confounds the ability to interpret data from the study.
  • Use of any other experimental drug or therapy within 28 days of study registration.
  • Known hypersensitivity reaction > grade 2 to thalidomide or structurally related compounds
  • The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
  • Any prior use of lenalidomide or liposomal doxorubicin
  • Concurrent use of other anti-cancer agents or treatments
  • Known positive for HIV or infectious hepatitis, type A, B or C
  • Uncontrolled hyper- or hypo- calcemia, glycosemia or thyroidism
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00903630
2008LS047, 0805M32463, WCC #50, RV-OVAR-PI-0447
Yes
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Celgene Corporation
Principal Investigator: Levi S. Downs, MD Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP